



International Journal of Pharmaceutical and Clinical Research

ISSN Print: 2664-7591
ISSN Online: 2664-7605
Impact Factor: RJIF 5.2
IJAN 2024; 6(1): 29-40
www.pharmaceuticaljournal.in
Received: 02-01-2024
Accepted: 05-02-2024

Dr. Anil Gorakhanath Korade
Associate Professor,
Department of Psychiatry,
Pravara Medical College, Loni,
Taluka Rahata, District,
Ahmednagar, Maharashtra,
India

Exploring role of Neurocognitive enhancers in dementia: A comprehensive review

Dr. Anil Gorakhanath Korade

DOI: <https://doi.org/10.33545/26647591.2024.v6.i1a.77>

Abstract

Dementia presents a significant public health challenge, with profound implications for affected individuals, families, and healthcare systems. Despite extensive research efforts, effective treatments to halt or reverse the progression of dementia remain elusive. Neurocognitive enhancers have emerged as a promising therapeutic approach to mitigate cognitive decline and improve quality of life for individuals with dementia. This comprehensive review examines the role of neurocognitive enhancers in dementia, focusing on pharmacological agents targeting various neurotransmitter systems and synaptic function. The review discusses the mechanisms of action, efficacy, safety profiles, and clinical use of neurocognitive enhancers, drawing insights from key clinical trials and studies. Additionally, the review explores challenges, limitations, and future directions in the field of neurocognitive enhancement for dementia care. By synthesizing evidence and providing critical analysis, this review aims to inform clinical practice, stimulate further research, and advance the management of dementia.

Keywords: Neurocognitive, modern healthcare, dementia, N-methyl-D-aspartate (NMDA)

Introduction

Dementia presents a complex and challenging landscape within modern healthcare, characterized by a gradual erosion of cognitive faculties and a decline in functional abilities [1]. Despite concerted endeavors in research and clinical practice, the pursuit of therapeutic interventions capable of arresting or reversing the underlying neurodegenerative processes remains ongoing. However, amidst this ongoing endeavor, the emergence of neurocognitive enhancers signifies a beacon of hope for individuals grappling with the burdens of dementia, offering the potential to alleviate symptoms and perhaps even enhance cognitive capabilities. The journey through dementia is marked by a progressive deterioration in cognitive function, impacting memory, reasoning, language, and perception, along with a decline in the ability to perform daily activities independently [1]. This pervasive decline not only challenges the affected individuals but also places a significant burden on their families and caregivers, as well as on healthcare systems globally. Despite the gravity of the challenge, recent advances in pharmacological research have illuminated promising pathways in the pursuit of alleviating the symptoms of dementia. Neurocognitive enhancers, a class of pharmacological agents designed to target and modulate various aspects of cognitive function, represent a notable stride in this endeavor. These agents operate through diverse mechanisms, including the modulation of neurotransmitter systems, enhancement of synaptic function, and protection against neurodegeneration [2]. In the realm of neurocognitive enhancement, cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine have emerged as foundational elements in the pharmacological armamentarium against dementia [3]. By inhibiting the breakdown of acetylcholine, a key neurotransmitter involved in cognitive processes, these agents bolster cholinergic neurotransmission, thereby mitigating cognitive symptoms in individuals affected by Alzheimer's disease and related dementias. Moreover, the introduction of memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has offered a complementary approach to dementia management [4]. By modulating glutamatergic neurotransmission, memantine helps shield against excitotoxicity and synaptic dysfunction, characteristic features of Alzheimer's pathology. The combined use of cholinesterase inhibitors and memantine in a synergistic therapeutic approach has demonstrated efficacy, particularly in advanced stages of the disease [5].

Corresponding Author:
Dr. Anil Gorakhanath Korade
Associate Professor,
Department of Psychiatry,
Pravara Medical College, Loni,
Taluka Rahata, District,
Ahmednagar, Maharashtra,
India

Despite such advancements, challenges persist in the realm of dementia pharmacotherapy, including variable treatment responses, adverse effects, and limitations in therapeutic efficacy. In light of these complexities, this comprehensive review endeavors to explore the intricate role of neurocognitive enhancers, encompassing both cholinesterase inhibitors and NMDA receptor antagonists, in the management of dementia. By unraveling their mechanisms of action and synthesizing evidence from clinical trials and meta-analyses, this review aims to provide insights to inform clinical practice and steer future research endeavors toward optimizing outcomes for individuals grappling with dementia. The spectrum of cognitive impairment, spanning from mild cognitive impairment (MCI) to severe dementia, highlights the pressing demand for pharmacological interventions to address the diverse needs of individuals along this continuum. In response to this imperative, a multitude of neurocognitive enhancers has been methodically crafted to target the cognitive deficits inherent in dementia. These pharmacological agents operate through a multifaceted array of mechanisms, encompassing the modulation of neurotransmitter systems, synaptic function, and neuroprotective pathways, all aimed at mitigating cognitive decline and enriching the overall quality of life for those grappling with dementia [2]. Mild cognitive impairment (MCI) represents an intermediary stage between normal aging and dementia, characterized by subtle yet noticeable cognitive changes that do not significantly impair daily functioning. Individuals with MCI often exhibit deficits in memory, attention, language, or other cognitive domains beyond what is expected for their age and education level. While not all individuals with MCI progress to dementia, the presence of MCI poses a heightened risk for future cognitive decline and warrants targeted interventions to potentially delay or prevent further deterioration [6]. As cognitive impairment progresses along the continuum, evolving into more severe forms of dementia, the need for effective pharmacological interventions becomes increasingly urgent. Neurocognitive enhancers, comprising a diverse pharmacotherapeutic arsenal, are strategically designed to address the intricate neurochemical imbalances and synaptic dysregulation that underlie cognitive decline in dementia. These agents exert their effects through various mechanisms, including enhancing cholinergic neurotransmission, modulating glutamatergic signaling, and promoting neuroprotection against neurodegenerative processes [2]. Cholinesterase inhibitors represent a cornerstone in the pharmacological management of dementia, particularly Alzheimer's disease, by augmenting cholinergic neurotransmission. Donepezil, rivastigmine, and galantamine are among the most widely prescribed cholinesterase inhibitors, functioning to inhibit the breakdown of acetylcholine and thereby bolstering cholinergic activity in the brain. This augmentation of cholinergic signaling is thought to ameliorate cognitive symptoms, such as memory loss and executive dysfunction, in individuals with dementia [3]. Additionally, the introduction of memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has enriched the pharmacotherapeutic landscape for moderate to severe Alzheimer's disease. Memantine works by modulating glutamatergic neurotransmission, thereby attenuating excitotoxicity and synaptic dysfunction associated with neurodegeneration. This neuroprotective effect offers a

complementary approach to cholinesterase inhibition, targeting different aspects of the pathophysiological cascade in Alzheimer's disease [4]. The integration of these neurocognitive enhancers into comprehensive treatment regimens underscores a holistic approach to dementia management, aiming not only to alleviate cognitive symptoms but also to enhance overall quality of life and functional independence for affected individuals. By targeting multiple facets of cognitive impairment, from neurotransmitter dysregulation to synaptic dysfunction and neurodegeneration, pharmacological interventions offer a promising avenue for mitigating the impact of dementia on individuals, families, and society at large. At the forefront of pharmacological interventions for Alzheimer's disease (AD) are cholinesterase inhibitors, including donepezil, rivastigmine, and galantamine. These medications constitute fundamental elements in the armamentarium against AD by targeting the dysregulation of acetylcholine, a neurotransmitter crucial for various cognitive processes such as learning, memory, and attention [3]. By impeding the breakdown of acetylcholine, cholinesterase inhibitors effectively elevate the levels of this neurotransmitter in the brain, thereby augmenting cholinergic neurotransmission. This augmentation serves to mitigate the cognitive symptoms experienced by individuals with AD, such as memory impairment, cognitive decline, and executive dysfunction. Moreover, memantine has emerged as a valuable therapeutic option for moderate to severe AD. As an N-methyl-D-aspartate (NMDA) receptor antagonist, memantine modulates glutamatergic neurotransmission, a process crucially involved in synaptic plasticity, learning, and memory [4]. By blocking excessive activation of NMDA receptors, memantine helps protect against excitotoxicity and synaptic dysfunction, both of which are hallmark features of AD pathology. This neuroprotective effect is particularly beneficial in mitigating neuronal damage and preserving cognitive function in individuals with moderate to severe AD. Together, the combination of cholinesterase inhibitors and memantine represents a multifaceted approach to AD treatment, targeting distinct yet complementary aspects of the underlying neurodegenerative processes. While cholinesterase inhibitors primarily enhance cholinergic neurotransmission to alleviate cognitive symptoms, memantine provides neuroprotection by modulating glutamatergic signaling, ultimately offering comprehensive therapeutic benefits for individuals grappling with the challenges of AD. The integration of cholinesterase inhibitors and memantine in combination therapy presents a synergistic strategy for effectively managing dementia [5]. Clinical trials have provided compelling evidence supporting the efficacy of this combined approach in enhancing both cognitive and functional outcomes, especially in advanced stages of the disease. Combining cholinesterase inhibitors with memantine capitalizes on their complementary mechanisms of action. While cholinesterase inhibitors primarily target the cholinergic deficit characteristic of dementia, memantine acts on glutamatergic dysregulation, offering a broader spectrum of neuroprotective effects. By simultaneously addressing multiple pathways implicated in dementia pathophysiology, combination therapy aims to provide a more comprehensive and synergistic treatment approach than monotherapy alone. Clinical studies have demonstrated that combination therapy yields superior outcomes

compared to either cholinesterase inhibitors or memantine alone, particularly in individuals with moderate to severe dementia. These benefits encompass improvements in cognitive function, daily living activities, and overall quality of life for patients and their caregivers. However, despite the promising results of combination therapy, several challenges persist in dementia pharmacotherapy. Treatment response variability among individuals, the occurrence of adverse effects, and therapeutic limitations underscore the ongoing need for research and innovation in this field. Continued exploration of novel therapeutic targets, optimization of treatment regimens, and the development of personalized approaches are imperative to address the multifaceted complexities of dementia and improve outcomes for affected individuals. The primary objective of this comprehensive review is to thoroughly explore the intricate role of neurocognitive enhancers, specifically focusing on cholinesterase inhibitors and NMDA receptor antagonists, in the treatment of dementia. By delving into the mechanisms of action underlying these pharmacological agents and synthesizing evidence derived from a wide array of clinical trials and meta-analyses, this review endeavors to provide a comprehensive understanding of their efficacy, safety, and clinical implications. Cholinesterase inhibitors, such as donepezil, rivastigmine, and galantamine, constitute a cornerstone of pharmacotherapy for dementia, particularly Alzheimer's disease. These agents exert their effects by inhibiting the breakdown of acetylcholine, a neurotransmitter critical for cognitive functions such as memory and attention. By preserving acetylcholine levels in the brain, cholinesterase inhibitors enhance cholinergic neurotransmission, thereby mitigating cognitive decline in individuals with dementia. In addition to cholinesterase inhibitors, NMDA receptor antagonists, exemplified by memantine, offer a complementary therapeutic approach for managing dementia. Memantine modulates glutamatergic neurotransmission by selectively blocking NMDA receptors, thus mitigating excitotoxicity and synaptic dysfunction associated with neurodegenerative processes. This neuroprotective effect holds particular promise for individuals with moderate to severe dementia, where synaptic dysfunction and neuronal damage are pronounced. By elucidating the mechanisms of action of these neurocognitive enhancers, this review aims to provide insights into their respective roles in dementia treatment. Furthermore, by synthesizing evidence from clinical trials and meta-analyses, the review seeks to offer a robust evidence base to inform clinical decision-making and guide future research endeavors aimed at optimizing treatment outcomes for individuals affected by dementia. Ultimately, through a comprehensive examination of neurocognitive enhancers, this review aspires to contribute to the advancement of clinical practice and the development of novel therapeutic strategies for addressing the multifaceted challenges posed by dementia. By leveraging insights gleaned from research and clinical experience, this review endeavors to foster improvements in dementia care and enhance the quality of life for individuals grappling with this debilitating condition.

Epidemiology of Dementia in India

Dementia presents a significant public health challenge in India, with its gravity expected to intensify markedly in the coming years owing to the aging population and increased

life expectancy [7]. While there is a scarcity of comprehensive nationwide studies detailing the prevalence and incidence of dementia, the existing data signal a substantial burden of the disease. India, like many other countries, is witnessing a demographic transition characterized by a growing proportion of elderly individuals. This demographic shift, coupled with advancements in healthcare leading to longer lifespans, sets the stage for a surge in the prevalence of age-related conditions such as dementia. As individuals age, the risk of developing dementia increases, amplifying the impact of population aging on the burden of the disease. Despite the lack of extensive nationwide studies, pockets of research and regional surveys provide glimpses into the prevalence and impact of dementia in India. These studies reveal significant variations in dementia prevalence across different regions and demographic groups, underscoring the complex interplay of sociodemographic factors, lifestyle, and genetic predispositions in shaping the disease burden. Moreover, the challenges inherent in diagnosing and managing dementia in resource-constrained settings further contribute to the underestimation of its true prevalence and incidence. Limited access to healthcare services, particularly in rural areas, coupled with cultural beliefs and stigma surrounding mental health issues, hinder accurate diagnosis and reporting of dementia cases.

Prevalence

Recent estimates indicate that dementia affects a significant proportion of individuals aged 60 years and older in India, with prevalence rates ranging from 2.7% to 10% [8]. However, the variability in these figures can be attributed to several factors, including differences in the study population, diagnostic criteria, and methodologies utilized across various research endeavors. A meta-analysis conducted by Shaji *et al.* revealed an overall prevalence of 3.5% among individuals aged 60 years and older. It is noteworthy that as individuals age, the prevalence of dementia tends to increase substantially. This age-related escalation is particularly pronounced among those aged 80 years and above, indicating a heightened vulnerability to dementia with advancing age. This age-dependent pattern underscores the profound impact of aging on cognitive health and highlights the need for targeted interventions and support systems tailored to meet the unique needs of older adults. Furthermore, the regional and demographic diversity within India contributes to variations in dementia prevalence across different geographic areas and population groups. Socioeconomic factors, educational attainment, lifestyle behaviors, and access to healthcare services all play significant roles in shaping the prevalence of dementia within specific communities and regions. As such, a nuanced understanding of these contextual factors is crucial for accurately assessing the burden of dementia and developing tailored strategies for prevention, diagnosis, and management.

Incidence

The scarcity of data on dementia incidence in India can be attributed primarily to the inherent challenges associated with conducting longitudinal studies and accurately diagnosing dementia in community settings. Unlike prevalence studies, which provide a snapshot of the existing cases within a population, incidence studies track the

emergence of new cases over time, necessitating long-term follow-up and meticulous diagnostic criteria. Despite these challenges, projections based on global trends suggest a looming surge in dementia incidence within India in the coming decades. This anticipated increase is driven by a confluence of factors, including demographic shifts, lifestyle modifications, and improvements in healthcare infrastructure leading to prolonged life expectancy. India, like many other countries, is experiencing a demographic transition marked by a rising proportion of elderly individuals. As the population ages, the risk of developing age-related conditions such as dementia escalates, amplifying the burden on healthcare systems and society at large. Moreover, changes in lifestyle and risk factors, such as sedentary behaviors, unhealthy dietary patterns, and increasing prevalence of chronic diseases like diabetes and cardiovascular conditions, contribute to the rising tide of dementia incidence. These lifestyle factors interact with genetic predispositions and environmental influences to shape individual susceptibility to dementia. Additionally, advancements in healthcare, including better access to medical care, improved management of chronic conditions, and enhanced public health initiatives, have contributed to increased longevity across the population. While this progress is undoubtedly laudable, it also brings with it the challenge of managing age-related conditions such as dementia, which become more prevalent as individuals live longer.

Burden

Dementia exerts a profound and far-reaching burden that extends well beyond the individuals directly affected by the condition. This burden encompasses not only the affected individuals themselves but also their families, caregivers, and the broader society. From an economic perspective, dementia imposes substantial healthcare expenses, including costs associated with diagnosis, treatment, and long-term care. Additionally, the condition leads to productivity loss as individuals affected by dementia may struggle to maintain employment or contribute to household income. This loss of productivity not only affects the individuals themselves but also has ripple effects on their families and society as a whole. The burden of dementia is not solely financial; it also encompasses significant social and emotional challenges. Family members and caregivers shoulder extensive caregiving responsibilities, providing support with daily activities, managing medications, and ensuring the safety and well-being of their loved ones with dementia. This caregiving role often comes at a considerable personal cost, leading to physical exhaustion, emotional stress, and financial strain. Moreover, the emotional toll of witnessing the decline of a loved one due to dementia can be devastating for family members and caregivers. The progressive nature of the disease means that caregivers may experience grief and loss as they witness the gradual deterioration of their loved one's cognitive and functional abilities. Furthermore, dementia can disrupt family dynamics and relationships, as caregivers may face challenges in balancing caregiving responsibilities with their own personal and professional lives. This strain on familial relationships can further exacerbate the emotional burden experienced by both the individuals with dementia and their caregivers.

Challenges

The accurate estimation and effective management of dementia in India are hindered by a multitude of challenges, each presenting unique obstacles that must be addressed to improve outcomes for affected individuals and their families. Firstly, there exists a pervasive lack of awareness and understanding surrounding dementia within Indian society. Many individuals, including both the general public and healthcare professionals, possess limited knowledge about the condition, its symptoms, and available treatment options. This lack of awareness often leads to delays in diagnosis and intervention, resulting in missed opportunities for early intervention and support. Moreover, dementia is still heavily stigmatized in Indian culture, leading to misconceptions, social isolation, and discrimination against those living with the condition and their families. Stigma can exacerbate feelings of shame and embarrassment among affected individuals and may deter them from seeking medical assistance or disclosing their symptoms to others, further perpetuating the cycle of ignorance and misunderstanding. In addition to societal attitudes, challenges related to healthcare infrastructure and resources pose significant barriers to effective dementia management in India. Many healthcare facilities lack the necessary equipment, specialized services, and trained personnel to diagnose and manage dementia effectively. Furthermore, access to dementia-specific care and support services, such as memory clinics and caregiver support groups, is limited, particularly in rural and underserved areas. Compounding these challenges is the scarcity of healthcare professionals with specialized training in dementia care. The shortage of geriatricians, neurologists, psychiatrists, and other healthcare providers equipped to diagnose and manage dementia further exacerbates the existing healthcare workforce crisis in India. Furthermore, India's cultural and linguistic diversity presents unique challenges in delivering dementia care. Culturally sensitive approaches to diagnosis, treatment, and support are essential to ensure that interventions are tailored to meet the diverse needs and preferences of individuals and families across different regions and communities.

Addressing the Growing Burden

To effectively tackle the growing burden of dementia in India, a comprehensive and multifaceted approach is essential, encompassing various key components aimed at improving prevention, diagnosis, treatment, and support for affected individuals and their families. Firstly, robust public health initiatives are needed to raise awareness about dementia, its risk factors, and symptoms, as well as to dispel misconceptions and reduce stigma surrounding the condition. These initiatives can take the form of educational campaigns, community outreach programs, and media campaigns targeting both the general public and healthcare professionals. By increasing awareness and understanding, individuals may be more likely to seek timely medical assistance and support. Furthermore, significant investments in healthcare infrastructure development are necessary to enhance the capacity of healthcare systems to diagnose, manage, and support individuals with dementia. This includes the establishment of specialized dementia clinics, memory centers, and geriatric services equipped with the necessary resources, equipment, and personnel trained in

dementia care. Additionally, efforts to integrate dementia care into primary healthcare settings can improve access to services, particularly in rural and underserved areas. Capacity building is another critical component of addressing the growing burden of dementia. This involves training healthcare professionals, including physicians, nurses, social workers, and caregivers, in dementia diagnosis, management, and support. Specialized training programs, workshops, and continuing education initiatives can equip healthcare providers with the knowledge and skills needed to deliver high-quality dementia care and support to affected individuals and their families. Community engagement plays a vital role in creating supportive environments for individuals with dementia and their caregivers. Community-based support services, such as day care centers, respite care facilities, and caregiver support groups, can provide much-needed assistance and respite to caregivers while promoting socialization and inclusion for individuals with dementia. Additionally, partnerships with local organizations, religious institutions, and community leaders can help foster dementia-friendly communities that are supportive and inclusive of individuals living with the condition. Early detection and diagnosis of dementia are paramount in improving outcomes and quality of life for affected individuals and their families. Screening programs, comprehensive geriatric assessments, and cognitive assessments can help identify individuals at risk of dementia at an early stage, enabling timely intervention and support. Access to appropriate healthcare services, including pharmacological and non-pharmacological interventions, can help manage symptoms, delay disease progression, and improve overall well-being.

Pathophysiology of Dementia

Dementia encompasses a heterogeneous group of neurodegenerative disorders characterized by progressive cognitive decline and functional impairment. Understanding the underlying pathophysiological mechanisms and neuropathological features associated with different types of dementia is essential for accurate diagnosis, prognosis, and targeted therapeutic interventions.

Alzheimer's Disease (AD)

Alzheimer's Disease (AD) holds its place as the primary cause of dementia worldwide, distinguished by the accumulation of amyloid-beta ($A\beta$) plaques and neurofibrillary tangles comprised of tau protein within the brain [9]. Central to comprehending AD pathophysiology is the amyloid cascade hypothesis, which suggests that the buildup of $A\beta$ peptides stems from abnormal processing of amyloid precursor protein (APP) [10]. This accumulation initiates a series of detrimental events, including synaptic dysfunction, neuroinflammation, and ultimately, neuronal demise. $A\beta$ plaques, resulting from the aggregation of $A\beta$ peptides, disrupt neuronal communication and homeostasis, contributing to the cognitive impairment observed in AD [11]. Furthermore, these plaques can elicit inflammatory responses, exacerbating neuronal damage and impairing brain function [12]. The involvement of tau protein pathology further complicates the understanding of AD. Tau, a microtubule-associated protein vital for maintaining neuronal structure and function, undergoes hyperphosphorylation and subsequent aggregation into neurofibrillary tangles [13]. This process closely correlates

with cognitive decline and neurodegeneration in AD, underscoring its pivotal role in disease progression. As tau pathology advances, it disrupts normal cellular processes, hindering intracellular transport and synaptic function. Consequently, this leads to the loss of neuronal integrity and eventual cell death, exacerbating cognitive decline and functional impairment characteristic of AD [14].

Vascular Dementia (VaD)

Vascular Dementia (VaD) arises as a consequence of cerebrovascular disorders, encompassing both ischemic and hemorrhagic lesions that inflict focal or diffuse damage upon the brain [15]. A hallmark neuropathological feature of VaD is small vessel disease, characterized by microinfarcts, lacunar infarcts, and white matter hyperintensities [16]. This pathology stems from chronic hypoperfusion and compromised cerebral blood flow, triggering a cascade of deleterious effects within the brain [17]. Neuronal injury ensues due to reduced oxygen and nutrient supply, leading to cellular dysfunction and ultimately cell death. Moreover, impaired blood flow contributes to white matter damage, disrupting neural pathways essential for cognitive function [18]. The cumulative impact of these vascular insults manifests as cognitive impairment characteristic of VaD. Depending on the location and extent of vascular lesions, individuals may experience a range of cognitive deficits, including memory impairment, executive dysfunction, and difficulties with attention and language [19]. Furthermore, the progression of VaD often follows a stepwise decline in cognitive function, reflecting the episodic nature of vascular insults and their cumulative effect on brain health [20]. In essence, VaD underscores the profound interplay between cerebrovascular pathology and cognitive decline, emphasizing the critical role of vascular health in maintaining cognitive function [21]. Understanding the underlying mechanisms of VaD is crucial for implementing preventive measures and targeted interventions aimed at preserving brain health and mitigating the progression of vascular-related cognitive impairment.

Lewy Body Dementia (LBD)

Lewy Body Dementia (LBD) stands as a multifaceted neurodegenerative condition characterized by the accumulation of abnormal protein aggregates, known as Lewy bodies, within the brain. These Lewy bodies predominantly consist of alpha-synuclein, a protein pivotal in regulating synaptic function and neurotransmitter release [22]. The presence of Lewy bodies instigates disruptions in various cellular processes, contributing to neuronal dysfunction and eventual degeneration. Specifically, these intraneuronal aggregates impede synaptic transmission, hampering communication between nerve cells and disrupting essential neuronal signaling pathways crucial for cognitive function [23]. Furthermore, Lewy body pathology impacts mitochondrial activity, the primary cellular source of energy production. Dysfunctional mitochondria exacerbate cellular stress and contribute to neuronal damage, further compromising brain function in individuals with LBD [24]. Moreover, the accumulation of alpha-synuclein disrupts protein degradation pathways within neurons, culminating in the accumulation of toxic protein aggregates and cellular waste products. This disruption in protein homeostasis adds to neuronal toxicity and accelerates the progression of neurodegeneration in LBD

[25]. Clinically, LBD manifests a diverse array of symptoms, including fluctuating cognition, visual hallucinations, and motor deficits reminiscent of Parkinson's disease. These symptoms reflect the widespread disruption of brain function attributed to Lewy body pathology, impacting both cognitive and motor domains [26].

Frontotemporal Dementia (FTD)

Frontotemporal Dementia (FTD) constitutes a diverse group of neurodegenerative disorders characterized by the gradual deterioration of the frontal and temporal lobes of the brain. This degeneration encompasses various pathological subtypes, including tauopathies and TDP-43 proteinopathies. Tauopathies in FTD involve the abnormal accumulation of tau protein, a microtubule-associated protein crucial for maintaining neuronal structure and function [27]. This accumulation disrupts normal cellular processes, leading to neuronal dysfunction and eventual degeneration within the affected brain regions. Tau pathology contributes to the impairment of cognitive functions associated with the frontal and temporal lobes, such as social behavior, executive function, and language processing. Conversely, TDP-43 proteinopathies in FTD are characterized by the presence of abnormal inclusions containing transactive response DNA-binding protein 43 (TDP-43) [28]. These inclusions disrupt cellular functions and contribute to the progressive decline in brain health observed in FTD patients. TDP-43 pathology further exacerbates cognitive deficits by interfering with normal synaptic transmission and neuronal communication within the frontal and temporal lobes. The cumulative impact of these pathological changes manifests as a spectrum of clinical symptoms in individuals with FTD. Disruption of social behavior, characterized by changes in personality and interpersonal interactions, is a hallmark feature of FTD [29]. Additionally, deficits in executive function, such as planning, organization, and problem-solving, are common in FTD patients. Language impairment, including difficulties with speech production, comprehension, and word finding, further contributes to the functional decline observed in individuals with FTD. In summary, understanding the underlying mechanisms of tauopathies and TDP-43 proteinopathies is essential for elucidating the complex pathophysiology of FTD [30]. This knowledge is pivotal for developing targeted therapeutic interventions aimed at mitigating cognitive decline and improving the quality of life for affected individuals.

Mixed Dementia

Mixed dementia is a multifaceted condition marked by the coexistence of various neuropathological processes contributing to cognitive decline. This often involves the concurrent presence of Alzheimer's disease (AD) pathology alongside cerebrovascular disease or Lewy body pathology [31]. In individuals with mixed dementia, the brain exhibits a blend of characteristic features from different neurodegenerative disorders. For example, patients may manifest both amyloid-beta ($A\beta$) plaques and tau protein neurofibrillary tangles associated with AD, alongside vascular lesions resulting from cerebrovascular disease or Lewy bodies indicative of Lewy body dementia [32]. The presence of multiple neuropathologies complicates the clinical presentation of mixed dementia, as patients may display overlapping symptoms associated with each

contributing pathology. This poses challenges in accurately diagnosing the condition and devising optimal treatment strategies [33]. Moreover, the diverse neuropathological makeup of mixed dementia necessitates a tailored therapeutic approach that addresses the distinct underlying mechanisms involved. This may entail a combination of interventions targeting AD-related pathology, vascular risk factors, and symptoms associated with Lewy body pathology [34].

Other Neurodegenerative Disorders

Among the spectrum of neurodegenerative disorders associated with dementia are Parkinson's disease dementia (PDD), Huntington's disease (HD), and prion diseases. PDD emerges from the accumulation of alpha-synuclein pathology in the context of Parkinson's disease, precipitating a gradual decline in cognitive function [35]. HD, on the other hand, is distinguished by the expansion of CAG repeats within the huntingtin gene, instigating neuronal dysfunction and eventual cell demise, particularly affecting regions like the striatum and cortex [36]. Prion diseases, exemplified by Creutzfeldt-Jakob disease (CJD), entail the misfolding and aggregation of prion protein, leading to swift cognitive deterioration and neurodegeneration [37]. These neurodegenerative conditions exhibit distinct neuropathological hallmarks and mechanisms contributing to dementia. A comprehensive understanding of their underlying pathology is essential for accurate diagnosis and the formulation of targeted therapeutic interventions aimed at ameliorating symptoms and impeding disease progression.

Dementia encompasses a diverse array of neurodegenerative disorders with distinct underlying pathophysiological mechanisms and neuropathological features. Understanding these mechanisms is crucial for accurate diagnosis and the development of targeted therapeutic strategies aimed at slowing disease progression and improving quality of life for affected individuals.

Current Treatment Landscape

The management of dementia involves a multifaceted approach aimed at alleviating symptoms, slowing disease progression, and improving quality of life for affected individuals. This includes both pharmacological and non-pharmacological interventions tailored to address cognitive, behavioral, and functional impairments associated with different types of dementia.

Pharmacological Interventions

Cholinesterase Inhibitors: Cholinesterase inhibitors, including donepezil, rivastigmine, and galantamine, are commonly prescribed for the treatment of Alzheimer's disease (AD). These agents work by inhibiting the breakdown of acetylcholine, a neurotransmitter involved in memory and cognitive function [38]. Clinical trials have demonstrated modest improvements in cognitive function and activities of daily living with cholinesterase inhibitors, particularly in mild to moderate AD [39]. Memantine: Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is approved for the treatment of moderate to severe AD. By modulating glutamatergic neurotransmission, memantine helps protect against excitotoxicity and synaptic dysfunction associated with AD pathology [40]. Memantine may be used alone or in combination with cholinesterase

inhibitors for synergistic effects in advanced stages of AD [41]. Antipsychotic Medications: Antipsychotic medications, such as risperidone and quetiapine, are sometimes prescribed to manage neuropsychiatric symptoms associated with dementia, including psychosis, agitation, and aggression. However, their use is limited due to the risk of serious adverse effects, including stroke, mortality, and cognitive decline [42]. Antidepressant Medications: Antidepressant medications, such as selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs), may be used to manage mood disturbances and behavioral symptoms in dementia. SSRIs are preferred due to their favorable side effect profile and lower risk of anticholinergic effects compared to TCAs [43].

Non-Pharmacological Interventions

Cognitive Stimulation: Cognitive stimulation interventions involve structured activities and exercises aimed at engaging cognitive functions such as memory, attention, and problem-solving. These interventions may include cognitive training programs, reminiscence therapy, and reality orientation techniques. Cognitive stimulation has been shown to improve cognitive function and quality of life in individuals with dementia [44]. **Physical Exercise:** Physical exercise, including aerobic exercise, strength training, and balance exercises, has been associated with cognitive benefits and improved functional outcomes in individuals with dementia. Exercise promotes neuroplasticity, neuroprotection, and vascular health, which may help mitigate cognitive decline and reduce the risk of falls and institutionalization [45]. **Multicomponent Interventions:** Multicomponent interventions combine various strategies, including cognitive training, physical exercise, and psychosocial support, to address multiple domains affected by dementia. These interventions may be delivered in community-based settings, residential care facilities, or through home-based programs. Multicomponent interventions have shown promise in improving cognitive function, mood, and quality of life in individuals with dementia [46].

Caregiver Support and Education: Support and education for caregivers are essential components of dementia management. Caregiver interventions may include education about dementia, training in caregiving skills, respite care services, and support groups. Addressing caregiver burden and providing practical support can enhance the well-being of both caregivers and individuals with dementia [47].

Neurocognitive enhancers play a crucial role in the management of dementia by targeting cognitive deficits and improving overall cognitive function in affected individuals. These pharmacological agents act through various mechanisms to alleviate symptoms and potentially slow disease progression. Here, we delve into the mechanisms of action, efficacy, safety, and clinical use of neurocognitive enhancers in dementia. Cholinesterase inhibitors (ChEIs), including donepezil, rivastigmine, and galantamine, stand as pivotal components within the pharmacological armamentarium for managing dementia, particularly Alzheimer's disease (AD). These agents function by impeding the action of acetylcholinesterase, the enzyme responsible for the degradation of acetylcholine, a neurotransmitter fundamental for memory and cognitive function [48]. The mechanism of action underlying ChEIs involves the augmentation of acetylcholine levels in the brain by preventing its breakdown. This action amplifies

cholinergic neurotransmission, consequently enhancing cognitive function [48]. Numerous clinical trials have corroborated the efficacy of ChEIs in ameliorating cognitive function, global clinical status, and activities of daily living among individuals afflicted with mild to moderate AD [49]. Despite their efficacy, ChEIs may entail common side effects such as gastrointestinal disturbances (e.g., nausea, vomiting, diarrhea), bradycardia, and insomnia. Nevertheless, these adverse effects are typically mild and transient [50].

Memantine, a notable neurocognitive enhancer, is an N-methyl-D-aspartate (NMDA) receptor antagonist that has gained approval for treating moderate to severe Alzheimer's disease (AD). Unlike cholinesterase inhibitors (ChEIs), which primarily target acetylcholine, memantine operates by modulating glutamatergic neurotransmission, thereby shielding against excitotoxicity and synaptic dysfunction [51]. Its mechanism of action involves the blockade of excessive activation of NMDA receptors by glutamate. This action helps regulate calcium influx and neuronal excitability, thereby forestalling neuronal damage and cognitive decline [51]. Clinical trials have underscored memantine's efficacy in modestly enhancing cognitive function, behavior, and activities of daily living in individuals grappling with moderate to severe AD [52]. From a safety perspective, memantine is generally well-tolerated. Reported side effects, such as dizziness, headache, and constipation, are infrequent and typically mild in nature [52]. In clinical practice, memantine may be employed as monotherapy or in combination with ChEIs for individuals afflicted with moderate to severe AD. It is often recommended for those who have not exhibited adequate responses to ChEI therapy or for those who are unable to tolerate ChEI treatment [53].

Combination therapy involving both cholinesterase inhibitors (ChEIs) and memantine has emerged as a viable approach for managing dementia in certain individuals. This therapeutic strategy aims to target multiple neurotransmitter systems implicated in the pathophysiology of dementia, potentially leading to synergistic effects and improved cognitive benefits [54]. The mechanism of action underlying combination therapy with ChEIs and memantine involves the simultaneous enhancement of cholinergic and glutamatergic neurotransmission. By addressing different aspects of dementia pathology, this dual-action approach may offer comprehensive therapeutic benefits [55]. Clinical evidence from trials has demonstrated that combination therapy may yield greater improvements in cognitive function, behavior, and overall clinical status compared to monotherapy with either ChEIs or memantine alone [56]. From a safety perspective, combination therapy is generally considered safe and well-tolerated, with side effects similar to those observed with monotherapy. However, careful monitoring is essential to assess individual responses and manage any adverse effects that may arise [57]. In clinical practice, combination therapy with ChEIs and memantine is typically reserved for individuals diagnosed with moderate to severe Alzheimer's disease (AD) who have not responded adequately to monotherapy or who exhibit rapidly progressive symptoms. This approach offers an additional treatment option for patients facing significant cognitive decline and challenges in daily functioning [57].

Clinical trials serve as pivotal tools in assessing the effectiveness of neurocognitive enhancers in managing dementia. Here, we present key findings from clinical trials

investigating the efficacy of cholinesterase inhibitors (ChEIs), including donepezil, rivastigmine, and galantamine, in individuals with dementia. a. Donepezil: Numerous clinical trials have underscored the efficacy of donepezil in enhancing cognitive function and overall clinical status among individuals with Alzheimer's disease (AD) [58]. For instance, a meta-analysis conducted by Birks and Harvey in 2006 revealed significant improvements in cognitive function associated with donepezil treatment compared to placebo across various cognitive assessment scales [59]. Furthermore, donepezil has demonstrated the ability to delay cognitive decline and enhance activities of daily living in individuals diagnosed with mild to moderate AD [60]. b. Rivastigmine: Clinical trials investigating rivastigmine have reported improvements in cognitive function, behavior, and activities of daily living among individuals with mild to moderate AD, as well as dementia associated with Parkinson's disease [61, 62]. Notably, a study by Cummings *et al.* in 1997 demonstrated significant enhancements in cognitive function in rivastigmine-treated patients compared to those receiving a placebo [63]. c. Galantamine: Galantamine has exhibited efficacy in improving cognitive function and global clinical status in individuals diagnosed with mild to moderate AD [64]. Clinical trials have consistently shown that galantamine treatment leads to notable improvements in cognitive function, as evidenced by various cognitive assessment scales, compared to placebo [65]. Additionally, galantamine has been associated with enhancements in activities of daily living and reductions in behavioral symptoms among AD patients [66].

Clinical trials have played a crucial role in establishing the efficacy of memantine in the treatment of moderate to severe Alzheimer's disease (AD). For instance, a study conducted by Reisberg *et al.* in 2003 demonstrated significant improvements in cognitive function, global clinical status, and activities of daily living among memantine-treated patients compared to those receiving a placebo [67]. Similarly, a randomized controlled trial by Tariot *et al.* in 2004 showed that memantine treatment led to notable enhancements in cognitive function and clinical status in AD patients who were already receiving donepezil [68].

Adverse effects and safety considerations are crucial when evaluating the use of neurocognitive enhancers in dementia management, particularly cholinesterase inhibitors (ChEIs) such as donepezil, rivastigmine, and galantamine. a. Donepezil: Common adverse effects of donepezil encompass gastrointestinal symptoms like nausea, vomiting, diarrhea, and anorexia. Less frequently reported adverse effects include insomnia, muscle cramps, and fatigue [69]. Rare but serious adverse effects like bradycardia, syncope, and seizures have been documented [70]. Furthermore, donepezil may interact with other medications metabolized by cytochrome P450 enzymes, potentially leading to drug interactions [71]. b. Rivastigmine: The adverse effects of rivastigmine resemble those of donepezil and may include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and anorexia. Additionally, rivastigmine can cause dizziness, headache, and urinary incontinence [72]. Serious adverse effects such as bradycardia, syncope, and falls have been reported, particularly among elderly patients [73]. Rivastigmine has the potential to interact with other

medications, especially those metabolized by cytochrome P450 enzymes [74]. c. Galantamine: Adverse effects associated with galantamine also include gastrointestinal symptoms like nausea, vomiting, diarrhea, and anorexia. Other reported adverse effects comprise dizziness, headache, and insomnia [75]. Rare but serious adverse effects like bradycardia, syncope, and seizures have been documented [76]. Galantamine may interact with other medications metabolized by cytochrome P450 enzymes, potentially leading to drug interactions [77]. Adverse effects of memantine are generally well-tolerated but should be closely monitored during dementia management. Common adverse effects may include dizziness, headache, confusion, and constipation [78]. Less frequently reported adverse effects encompass hypertension, hallucinations, and agitation [79]. While serious adverse effects such as seizures and cardiovascular events are rare, they have been reported, particularly in patients with underlying risk factors [80]. Importantly, memantine exhibits a low potential for drug interactions, primarily due to its excretion unchanged in the urine and minimal impact on cytochrome P450 enzymes [81]. Despite their generally favorable tolerability profile, healthcare providers must carefully weigh the potential risks and benefits of neurocognitive enhancers like ChEIs and memantine in individual patients. Factors such as comorbidities, concomitant medications, and patient preferences should be considered to optimize treatment outcomes and minimize adverse events.

Challenges and Limitations

The integration of neurocognitive enhancers into dementia care faces several challenges and limitations that must be addressed for optimal treatment outcomes. One significant challenge is medication adherence, particularly among patients with cognitive impairment, which can result in suboptimal response to treatment [82]. Additionally, the efficacy of neurocognitive enhancers may vary among individuals, with some experiencing minimal cognitive improvement despite treatment [82]. Adverse effects, such as gastrointestinal symptoms and dizziness, pose another limitation to the tolerability of these medications, potentially leading to discontinuation or dose adjustments [82]. Moreover, there is ongoing controversy regarding the long-term efficacy of neurocognitive enhancers in slowing the progression of dementia. While these medications may provide temporary relief from symptoms, they do not address the underlying neurodegenerative process associated with the condition [82]. Furthermore, the cost of neurocognitive enhancers can present a significant barrier to access, particularly for patients in low-resource settings or those without adequate insurance coverage [83]. This financial burden may restrict treatment options and limit the availability of these medications to those who could benefit from them. Addressing these challenges requires a multifaceted approach that considers not only the pharmacological aspects of treatment but also patient education, caregiver support, and healthcare infrastructure improvements. By addressing barriers to adherence, optimizing medication management, and promoting access to affordable treatment options, healthcare providers can better support individuals with dementia and improve their quality of life.

Patient Perspectives and Quality of Life

In the realm of dementia treatment, understanding patient perspectives and considerations related to quality of life is paramount. While neurocognitive enhancers hold promise in improving cognitive function, their impact on overall quality of life for individuals with dementia is nuanced. Adverse effects, caregiver burden, and challenges in daily functioning can significantly influence patients' subjective well-being [84]. One notable aspect is the potential discrepancy between the perceived benefits of medication and the reality of its effects. Patients may experience adverse effects that outweigh the cognitive improvements, leading to a diminished overall quality of life. Additionally, the burden on caregivers, who play a pivotal role in medication management and providing support, can indirectly affect patients' well-being [84]. Furthermore, individuals with dementia may exhibit anosognosia, a limited awareness or understanding of their cognitive decline. This lack of insight can pose challenges in medication adherence and treatment acceptance. As a result, involving patients in shared decision-making processes becomes imperative, allowing their preferences and values to guide treatment decisions.

Caregiver Burden and Support

The role of caregivers in supporting individuals with dementia is indispensable, yet it comes with substantial challenges and burdens. Caregivers are tasked with managing the multifaceted needs of dementia patients, ranging from medication administration to addressing behavioral symptoms and assisting with daily activities. The demands of caregiving can exact a toll on caregivers' physical and emotional well-being. The relentless nature of caregiving responsibilities, coupled with the progressive nature of dementia, can lead to feelings of stress, anxiety, and exhaustion. Moreover, witnessing the cognitive decline and behavioral changes in their loved ones can evoke a sense of grief and loss for caregivers. Recognizing the pivotal role of caregivers, it is imperative to provide them with adequate support and resources. Caregiver-focused interventions have been shown to mitigate caregiver burden and enhance coping mechanisms. These interventions encompass a spectrum of services, including caregiver education, respite care programs, and support groups. Education programs equip caregivers with essential knowledge about dementia, its progression, and strategies for managing symptoms effectively. Respite care services offer caregivers temporary relief from their caregiving duties, allowing them to recharge and attend to their own needs. Support groups provide a platform for caregivers to connect with others facing similar challenges, fostering a sense of community and solidarity.

Cultural and Societal Context

Cultural and societal contexts exert profound influence on the provision of dementia care and treatment strategies. Varied cultural perspectives on aging, dementia, and the roles of family caregivers significantly shape help-seeking behaviors and treatment preferences within different communities. Across cultures, perceptions of aging and cognitive decline may vary widely. Cultural beliefs, traditions, and values often inform attitudes towards dementia, affecting the acceptance of diagnosis and engagement with healthcare services. Stigma surrounding

dementia can compound these challenges, leading to delays in seeking medical attention and reluctance to discuss symptoms openly. Ethical dilemmas further complicate dementia care, particularly concerning the use of neurocognitive enhancers and decision-making processes for patients lacking capacity. Balancing autonomy and beneficence becomes crucial when considering treatment options for individuals with impaired decision-making abilities [89]. Cultural competence is essential in navigating these complexities, ensuring that care practices align with the values and preferences of patients and their families. Healthcare providers must demonstrate sensitivity to cultural nuances and engage in culturally competent care practices to deliver person-centered care effectively. By acknowledging and respecting diverse cultural perspectives, healthcare professionals can foster trust, enhance communication, and promote equitable access to dementia care services across diverse populations.

Future Directions and Research Implications

Future research directions in neurocognitive enhancers and dementia care are essential for advancing our understanding and addressing current challenges in the field. Longitudinal studies are crucial to evaluate the sustained efficacy and safety of neurocognitive enhancers over extended periods, especially in diverse patient populations. Exploring novel therapeutic targets and interventions represents a promising avenue for future research. Investigating mechanisms underlying neurodegeneration, such as neuroinflammation and synaptic dysfunction, could lead to the development of more targeted and effective treatments for dementia. Multimodal approaches that combine pharmacological interventions with non-pharmacological strategies, such as cognitive stimulation and physical exercise, may offer synergistic benefits and improve overall outcomes for individuals with dementia. Furthermore, research efforts should prioritize interventions that support caregivers and promote their well-being. Caregiver-focused interventions, including education, respite care, and support groups, are crucial for alleviating caregiver burden and enhancing the quality of care provided to individuals with dementia. Understanding the cultural and societal context of dementia care is paramount for developing culturally sensitive interventions and reducing disparities in access to care. Research initiatives should strive to incorporate diverse perspectives and experiences to ensure that interventions are relevant and effective across different populations. By addressing these research priorities, we can advance dementia care and ultimately improve outcomes for individuals living with this condition and their caregivers. This collaborative effort will contribute to enhancing the quality of life and well-being of those affected by dementia.

Conclusion

The integration of neurocognitive enhancers stands as a cornerstone in the management of dementia, albeit with inherent complexities and constraints. A holistic approach to dementia care mandates an understanding of patient perspectives, acknowledgment of caregiver burden, and sensitivity to cultural nuances. The consideration of patient viewpoints assumes paramount importance, fostering a tailored and empathetic treatment approach that respects individual needs and preferences. Simultaneously, addressing caregiver burden emerges as a critical

imperative, recognizing their pivotal role in safeguarding the well-being of individuals with dementia. Equipping caregivers with adequate support and resources enables them to navigate the intricate landscape of dementia care while preserving their own health and resilience. Moreover, cultural considerations hold significant sway in shaping interventions for diverse populations, ensuring that care strategies resonate with local beliefs, values, and practices. Embracing the diversity of perspectives surrounding dementia fosters the delivery of culturally sensitive and inclusive care across various societal contexts. In charting the path forward, future research endeavors should prioritize bridging existing knowledge gaps and spearheading innovative approaches to dementia treatment and caregiver support. Longitudinal studies assume pivotal importance in delineating the enduring efficacy and safety profiles of neurocognitive enhancers, while also exploring novel therapeutic avenues. A multidisciplinary approach that amalgamates pharmacological and non-pharmacological modalities holds promise in optimizing dementia care outcomes and enriching the quality of life for both individuals with dementia and their caregivers

Source and funding: No

Conflict of interest: No conflict of interest

References

- Cummings JL. Alzheimer's disease. *N Engl J Med*. 2004 Jul 1;351(1):56-67.
- Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. *Lancet*. 2011 Mar 19;377(9770):1019-31.
- McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, *et al*. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. *Neurology*. 2017 Jul 4;89(1):88-100.
- Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, *et al*. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain*. 2011 Sep 1;134(9):2456-77.
- Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. *Cochrane Database Syst Rev*. 2006 Jan 25;(1):CD001190.
- Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. Memantine in moderate-to-severe Alzheimer's disease. *N Engl J Med*. 2003 Mar 20;348(12):1333-41.
- Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, *et al*. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. *Lancet*. 2021 Sep 4;398(10312):872-84.
- Lancôt KL, Herrmann N, Mazzotta P, Khan LR. Evaluation of cholinesterase inhibitor safety in patients with Alzheimer disease. *Can J Psychiatry*. 2004 May;49(4):249-57.
- Tan CC, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, *et al*. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. *J Alzheimers Dis*. 2014;41(2):615-31.
- Doraiswamy PM, Leon J, Cummings JL, Marin D, Neumann PJ, Preux PM. Prevalence and impact of medical comorbidity in Alzheimer's disease. *J Gerontol A Biol Sci Med Sci*. 2002 Mar;57(3):M173-7.
- Higgins JP, Green S. *Cochrane handbook for systematic reviews of interventions*. Vol 4. Chichester (UK): John Wiley & Sons; 2011.
- Swaminathan A, Jicha GA. Nutrition and prevention of Alzheimer's dementia. *Front Aging Neurosci*. 2009 Mar 31;1:8.
- Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, *et al*. Dementia prevention, intervention, and care. *Lancet*. 2017 Dec 16;390(10113):2673-734.
- Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, *et al*. Vitamin E and donepezil for the treatment of mild cognitive impairment. *N Engl J Med*. 2005 Jun 9;352(23):2379-88.
- Mulsant BH, Pollock BG, Kirshner M, Shen C, Dodge H, Ganguli M, *et al*. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. *Arch Gen Psychiatry*. 2003 Feb;60(2):198-203.
- Cummings JL. Alzheimer's disease. *N Engl J Med*. 2004;351(1):56-67.
- Petersen RC, Thomas RG, Grundman M, *et al*. Vitamin E and donepezil for the treatment of mild cognitive impairment. *N Engl J Med*. 2005;352(23):2379-2388.
- Birks J. Cholinesterase inhibitors for Alzheimer's disease. *Cochrane Database Syst Rev*. 2006;1:CD005593.
- Tariot PN, Farlow MR, Grossberg GT, *et al*. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. *JAMA*. 2004;291(3):317-324.
- Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. *Cochrane Database Syst Rev*. 2006;1:CD001747.
- Farlow MR. NMDA receptor antagonists: A new therapeutic approach for Alzheimer's disease. *Geriatrics*. 2002;57 Suppl 1:S9-12.
- Geldmacher DS. Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care. *Prim Care Companion J Clin Psychiatry*. 2002;4(2):51-59.
- Aisen PS, Schafer KA, Grundman M, *et al*. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. *JAMA*. 2003;289(21):2819-2826.
- Sevigny J, Chiao P, Bussière T, *et al*. The antibody aducanumab reduces A β plaques in Alzheimer's disease. *Nature*. 2016;537(7618):50-56.
- Honig LS, Vellas B, Woodward M, *et al*. Trial of solanezumab for mild dementia due to Alzheimer's disease. *N Engl J Med*. 2018;378(4):321-330.
- Wischik CM, Staff RT, Wischik DJ, Bentham P, Murray AD, Storey JMD. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease. *J Alzheimers Dis*. 2015;44(2):705-720.
- Wilkinson D, Windfeld K, Colding-Jørgensen E. Safety and efficacy of idalopirdine, a 5-HT₆ receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind,

- placebo-controlled phase 2 trial. *Lancet Neurol.* 2014;13(11):1092-1099.
28. Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. *Arch Neurol.* 2011;68(8):991-998.
 29. Porsteinsson AP, Grossberg GT, Mintzer J, *et al.* Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. *Curr Alzheimer Res.* 2008;5(1):83-89.
 30. Lutz A, Slagter HA, Dunne JD, Davidson RJ. Attention regulation and monitoring in meditation. *Trends Cogn Sci.* 2008;12(4):163-169.
 31. Smith ME, Farah MJ. Are prescription stimulants "smart pills"? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. *Psychol Bull.* 2011;137(5):717-741.
 32. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. *Cochrane Database Syst Rev.* 2006;1:CD001747.
 33. Brunoni AR, Vanderhasselt MA. Working memory improvement with non-invasive brain stimulation of the dorsolateral prefrontal cortex: a systematic review and meta-analysis. *Brain Cogn.* 2014;86:1-9.
 34. Anguera JA, Boccanfuso J, Rintoul JL, *et al.* Video game training enhances cognitive control in older adults. *Nature.* 2013;501(7465):97-101.
 35. Farah MJ, Illes J, Cook-Deegan R, *et al.* Neurocognitive enhancement: what can we do and what should we do? *Nat Rev Neurosci.* 2004;5(5):421-425.
 36. Prince M, Bryce R, Albanese E, *et al.* The global prevalence of dementia: a systematic review and metaanalysis. *Alzheimers Dement.* 2013;9(1):63-75.e2.
 37. Shaji KS, Jotheeswaran AT, Girish N, *et al.* The dementia India report: prevalence, impact, costs and services for dementia. 2010. Accessed January 15, 2024. https://www.who.int/mental_health/neurology/dementia/Report_on_Dementia_in_India.pdf
 38. Shaji S, Bose S, Verghese A. Prevalence of dementia in an urban population in Kerala, India. *Br J Psychiatry.* 2005;186:136-140.
 39. Llibre Rodriguez JJ, Ferri CP, Acosta D, *et al.* Prevalence of dementia in Latin America, India, and China: a population-based cross-sectional survey. *Lancet.* 2008;372(9637):464-474.
 40. Patel V, Prince M. Ageing and mental health in a developing country: who cares? Qualitative studies from Goa, India. *Psychol Med.* 2001;31(1):29-38.
 41. Kumar R, Kar N, Misra AK, *et al.* Study of stigma among patients with Alzheimer's disease attending a tertiary care hospital in eastern India. *Dementia (London).* 2017;16(2):225-235.
 42. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science.* 2002;297(5580):353-356.
 43. Wang Y, Mandelkow E. Tau in physiology and pathology. *Nat Rev Neurosci.* 2016;17(1):5-21.
 44. Iadecola C. The pathobiology of vascular dementia. *Neuron.* 2013;80(4):844-866.
 45. Irwin DJ, Lee VMY, Trojanowski JQ. Parkinson's disease dementia: convergence of α -synuclein, tau and amyloid- β pathologies. *Nat Rev Neurosci.* 2013;14(9):626-636.
 46. Armstrong MJ, Litvan I, Lang AE, *et al.* Criteria for the diagnosis of corticobasal degeneration. *Neurology.* 2013;80(5):496-503.
 47. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. *Neurology.* 2007;69(24):2197-2204.
 48. Aarsland D, Creese B, Politis M, *et al.* Cognitive decline in Parkinson disease. *Nat Rev Neurol.* 2017;13(4):217-231.
 49. Bates GP, Dorsey R, Gusella JF, *et al.* Huntington disease. *Nat Rev Dis Primers.* 2015;1:15005.
 50. Prusiner SB. Prions. *Proc Natl Acad Sci U S A.* 1998;95(23):13363-13383.
 51. Birks JS. Cholinesterase inhibitors for Alzheimer's disease. *Cochrane Database Syst Rev.* 2006;(1):CD005593.
 52. Howard R, McShane R, Lindesay J, *et al.* Donepezil and memantine for moderate-to-severe Alzheimer's disease. *N Engl J Med.* 2012;366(10):893-903.
 53. Reisberg B, Doody R, Stöffler A, *et al.* Memantine in moderate-to-severe Alzheimer's disease. *N Engl J Med.* 2003;348(14):1333-1341.
 54. Tariot PN, Farlow MR, Grossberg GT, *et al.* Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. *JAMA.* 2004;291(3):317-324.
 55. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. *JAMA.* 2005;294(15):1934-1943.
 56. Sepehry AA, Sarai M, Sepehry RA. Systematic review of pharmacological treatments in persons with Lewy body dementia. *Am J Geriatr Psychiatry.* 2012;20(10):866-879.
 57. Woods B, Aguirre E, Spector AE, *et al.* Cognitive stimulation to improve cognitive functioning in people with dementia. *Cochrane Database Syst Rev.* 2012;(2):CD005562.
 58. Forbes D, Thiessen EJ, Blake CM, *et al.* Exercise programs for people with dementia. *Cochrane Database Syst Rev.* 2013;(12):CD006489.
 59. Guerra M, Ferri CP, Fonseca M, *et al.* Multisensory stimulation in individuals with dementia: a systematic review. *Int Psychogeriatr.* 2019;31(1):23-39.
 60. Brodaty H, Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. *Am J Psychiatry.* 2012;169(9):946-953.
 61. Birks JS. Cholinesterase inhibitors for Alzheimer's disease. *Cochrane Database Syst Rev.* 2006;(1):CD005593.
 62. Howard R, McShane R, Lindesay J, *et al.* Donepezil and memantine for moderate-to-severe Alzheimer's disease. *N Engl J Med.* 2012;366(10):893-903.
 63. Farlow MR. Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care. *Prim Care Companion J Clin Psychiatry.* 2006;8(3):152-158.
 64. Reisberg B, Doody R, Stöffler A, *et al.* Memantine in moderate-to-severe Alzheimer's disease. *N Engl J Med.* 2003;348(14):1333-1341.
 65. Tariot PN, Farlow MR, Grossberg GT, *et al.* Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a

- randomized controlled trial. *JAMA*. 2004;291(3):317-324.
66. Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. *Int J Geriatr Psychiatry*. 2008;23(5):537-545.
 67. Atri A. Combination therapy in Alzheimer's disease: an interim analysis of the clinical experience with donepezil plus memantine. *Expert Rev Neurother*. 2011;11(6):815-825.
 68. Howard R, McShane R, Lindesay J, *et al*. Donepezil and memantine for moderate-to-severe Alzheimer's disease. *N Engl J Med*. 2012;366(10):893-903.
 69. Howard R, McShane R, Lindesay J, *et al*. Donepezil and memantine for moderate-to-severe Alzheimer's disease. *N Engl J Med*. 2012;366(10):893-903.
 70. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. *Cochrane Database Syst Rev*. 2006;(1):CD001190.
 71. Doody RS, Geldmacher DS, Gordon B, *et al*. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. *Arch Neurol*. 2001;58(3):427-433.
 72. Rösler M, Anand R, Cicin-Sain A, *et al*. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. *BMJ*. 1999;318(7184):633-638.
 73. Emre M, Aarsland D, Albanese A, *et al*. Rivastigmine for dementia associated with Parkinson's disease. *N Engl J Med*. 2004;351(24):2509-2518.
 74. Cummings JL, McRae T, Zhang R, *et al*. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. *Am J Geriatr Psychiatry*. 1997;5(4):369-378.
 75. Tariot PN, Solomon PR, Morris JC, *et al*. A 5-month, randomized, placebo-controlled trial of galantamine in AD. *Neurology*. 2000;54(12):2269-2276.
 76. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. *BMJ*. 2000;321(7274):1445-1449.
 77. Cummings JL, Schneider E, Tariot PN, *et al*. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. *Neurology*. 2006;67(1):57-63.
 78. Reisberg B, Doody R, Stöfler A, *et al*. Memantine in moderate-to-severe Alzheimer's disease. *N Engl J Med*. 2003;348(14):1333-1341.
 79. Tariot PN, Farlow MR, Grossberg GT, *et al*. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. *JAMA*. 2004;291(3):317-324.
 80. Donepezil Prescribing Information. [https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020690s046,021720s0211bl.pdf]
 81. Birks J, Grimley Evans J. Rivastigmine for Alzheimer's disease. *Cochrane Database Syst Rev*. 2015;4(4):CD001191.
 82. Gaist D, García Rodríguez LA, Hellfritsch M, Poulsen FR, Halle B, Hallas J, Pottegård A. Association of antiepileptic drug use with risk of suicide. *JAMA Neurology*. 2019 Jan 1;76(1):68-74.
 83. Rivastigmine Prescribing Information. [https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021083s0261bl.pdf]
 84. Yerba Mate's Mechanism of Action against Alzheimer's Disease Involves the Attenuation of Oxidative Stress in Rat Brain Cortex. [<https://www.hindawi.com/journals/omcl/2020/5695430/>]
 85. Rivastigmine and Parkinson's Disease: A Systematic Review of Randomized Controlled Trials. [<https://pubmed.ncbi.nlm.nih.gov/26123129/>]
 86. Galantamine Prescribing Information. [https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021615s0331bl.pdf]
 87. Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Lozupone M, Santamato A, Zecca C, Barulli MR, Bellomo A, Pilotto A, Daniele A. Tau-centric targets and drugs in clinical development for the treatment of Alzheimer's disease. *BioMed Research International*. 2016;2016.
 88. Galantamine: pharmacological characteristics and application in the treatment of Alzheimer's disease. [<https://pubmed.ncbi.nlm.nih.gov/16639398/>]
 89. Memantine Prescribing Information. [https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021487s0361bl.pdf]
 90. Memantine-associated reversible acute kidney injury: A case report and literature review. [<https://pubmed.ncbi.nlm.nih.gov/29697624/>]
 91. Gugliotta R. Memantine and cholinesterase inhibitors: uses and safety concerns. *Clin Interv Aging*. 2007;2(1):207-212.
 92. Alzheimer's Association. (2020). Medications for Memory Loss.
 93. Prince M, Ali GC, Guerchet M, Prina AM, Albanese E, Wu YT. Recent global trends in the prevalence and incidence of dementia, and survival with dementia. *Alzheimers Res Ther*. 2016;8(1):1-13.
 94. Werner P, Mittelman MS. Quality of life and social-psychological adaptation to aging in dementia patients and caregivers. In: *Handbook of Dementia Care: International Perspectives in Primary and Secondary Care*. 2019:125.
 95. Manthorpe J, Iliffe S. Dementia: universal health coverage must include access to treatment and care. *BMJ*. 2019;365:l2179.
 96. Brodaty H, Donkin M. Family Carers in Dementia: A Literature Review of Their Psychosocial Needs, Interventions and Models of Support. *Health Soc Care Community*. 2009;17(2):135-147.
 97. Gitlin LN, Marx K, Stanley IH, Hodgson N. Translating evidence-based dementia caregiving interventions into practice: State-of-the-science and next steps. *Gerontologist*. 2015;55(2):210-226.
 98. Mukadam N, Cooper C, Livingston G. A systematic review of ethnicity and pathways to care in dementia. *Int J Geriatr Psychiatry*. 2011;26(1):12-20.
 99. Gauthier S, Albert M. Ethical considerations in clinical trials for Alzheimer's disease: A position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. *Alzheimers Dement*. 2019;15(7):1037-1043.